A PHASE 2A, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO EVALUATE THE EFFICACY, SAFETY, TOLERABILITY AND PHARMACOKINETICS OF PF-06687234 AS ADD-ON THERAPY TO INFLIXIMAB IN ACTIVE ULCERATIVE COLITIS SUBJECTS WHO ARE NOT IN REMISSION (BUILD UC)

drug protocol number

B7581002

drug sponsor

Pfizer

drug study

PF-06687234

drug trial site

King Abdulaziz Medical City NG (Riyadh), King Abdulaziz University Hospital (Jeddah), King Khalid University Hospital (Riyadh)

drug status

Ongoing

drug phase